A rationally designed mutant of plasma platelet-activating factor acetylhydrolase hydrolyzes the organophosphorus nerve agent soman  by Kirby, Stephen D. et al.
Biochimica et Biophysica Acta 1854 (2015) 1809–1815
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbapapA rationally designed mutant of plasma platelet-activating factor
acetylhydrolase hydrolyzes the organophosphorus nerve agent soman☆Stephen D. Kirby a,b,⁎, Joseph Norris a, Richard Sweeney a, Brian J. Bahnson b, Douglas M. Cerasoli a
a U.S. Army Medical Research Institute of Chemical Defense, APG, MD 21010, United States
b Department of Chemistry & Biochemistry, University of Delaware, Newark, DE 19716, United StatesAbbreviations: OP, organophosphorus compoun
compounds; AChE, acetylcholinesterase; pPAF-AH, pla
acetylhydrolase; BuChE, butyrylcholinesterase; CaE, carbo
angstroms; PAF, platelet-activating factor; LDL, low densit
lipoprotein; PDB, Protein Data Bank; VMD, Visual Molecu
Molecular Operating Environment program; EDTA, ethyle
optical density; A600, absorbance at 600 nm; IPTG, isopropy
DTT, dithiothreitol; PNPB, para-nitrophenyl butyrate; Ɛ, e
velocity; KM, Michaelis–Menten binding constant; Vmax, m
number; Ki, inhibition constant; DTNB, 5,5′-dithiobis-2-
chromatography/mass spectrometry; DFP, diisopropyl ﬂ
charge ratio; kcat/KM, catalytic efﬁciency; i-face, interface b
(−) enantiomer; PR, phosphorus (+) enantiomer; CS, carb
(+) enantiomer; PON1, paraoxonase-1; GB, sarin; GD, som
☆ This research was supported by the Defense Threat Re
and Technology Ofﬁce, Medical S&T Division. Funding was
8P30GM103519 from the National Institute of Ge
5R01HL084366 from the National Heart, Lung, and Bloo
expressed in this manuscript are those of the authors and
of the Department of Army, Department of Defense, or th
⁎ Corresponding author at: Research Division, Physiolog
ArmyMedical Research Institute of Chemical Defense, 310
21010-5400, United States.
E-mail address: stephen.d.kirby.civ@mail.mil (S.D. Kirb
http://dx.doi.org/10.1016/j.bbapap.2015.09.001
1570-9639/Published by Elsevier B.V. This is an open accea b s t r a c ta r t i c l e i n f oArticle history:
Received 12 May 2015
Received in revised form 21 July 2015
Accepted 1 September 2015
Available online 3 September 2015
Keywords:
Nerve agents
Organophosphorus compounds
Plasma platelet-activating factor
acetylhydrolase
Bioscavenger
SomanOrganophosphorus compounds (OPs) such as sarin and soman are some of themost toxic chemicals synthesized
by man. They exert toxic effects by inactivating acetylcholinesterase (AChE) and bind secondary target protein.
Organophosphorus compounds are hemi-substrates for enzymes of the serine hydrolase superfamily. Enzymes
can be engineered by amino acid substitution into OP-hydrolyzing variants (bioscavengers) and used as thera-
peutics. Some enzymes associated with lipoproteins, such as human plasma platelet-activating factor
acetylhydrolase (pPAF-AH), are also inhibited by OPs; these proteins have largely been ignored for engineering
purposes because of complex interfacial kinetics and a lack of structural data. We have expressed active
human pPAF-AH in bacteria and previously solved the crystal structure of this enzyme with OP adducts. Using
these structures as a guide, we created histidine mutations near the active site of pPAF-AH (F322H, W298H,
L153H) in an attempt to generate novel OP-hydrolase activity. Wild-type pPAF-AH, L153H, and F322H have
essentially no hydrolytic activity against the nerve agents tested. In contrast, the W298H mutant displayed
novel somanase activity with a kcat of 5 min−1 and a KM of 590 μM at pH 7.5. There was no selective preference
for hydrolysis of any of the four soman stereoisomers.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Anti-cholinesterase organophosphorus compounds (OPs) such as
the chemical warfare nerve agents sarin and soman (Fig. 1A), are
among the most toxic substances synthesized by man, being highly le-
thal for mammals [1]. They pose a lethal threat to human life because
they rapidly inhibit acetylcholinesterase (AChE), but they also inhibit
other enzyme targets [2]. Current chemotherapeutic countermeasures
against OP intoxication are effective, but can result in behavioral
incapacitation and can have deleterious side effects if not given within
a prescribed time frame after OP exposure or if their dosage is too
high [1]. These unwanted side effects have necessitated the develop-
ment of more efﬁcacious alternative measures such as enzymes that
neutralize or scavenge nerve agents (bioscavengers) and have little or
no side effects [3]. Bioscavengers can bind and, in an ideal scenario,
hydrolyze nerve agents in the plasma before they reach AChE targets
in the peripheral and central nervous systems.
Organophosphorus compounds are potent inhibitors of enzymes
of the serine hydrolase superfamily, which includes AChE, butyrylcholin-
esterase (BuChE), carboxylesterase (CaE) and plasma platelet-activating
factor acetylhydrolase (pPAF-AH; EC 3.1.1.47). They act as hemi-
substrates for these enzymes but become “locked” at the phosphorylation
step as shown in Fig. 1B. Typically, thedephosphorylation step is extreme-
ly slow because of unfavorable stereochemistry adopted around theense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Organophosphorus nerve agents reactwith serine hydrolases such as AChE or pPAF-AH. Panel A shows the structures of the OP compounds soman (GD), tabun (GA), sarin (GB) and
cyclosarin (GF). Panel B shows the reaction of a mutant serine hydrolase with sarin as a representative OP compound. The ﬁrst step forms a phosphorylated enzyme. In the second step, a
water molecule is shown attacking the phosphorylated enzyme, activated by a general base catalyst (−B:; H298).
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from hydrolyzing the adducted phosphoryl group. Thus, enzymes of the
serine hydrolase superfamily have the potential to be re-engineered
through speciﬁc mutations into OP-hydrolyzing platforms that can be
used as catalytic scavengers to afford protection against OP toxicity [4].
Starting from the structure of an inactivated serine hydrolase, site-
directed mutations of amino acid residues surrounding the active site
within 4–10Å can inﬂuence interactions between the phosphorylated ac-
tive site serine and an activated water molecule to enhance hydrolysis.
Historically, the enzymes found in the plasma that bind nerve agents
(such as BuChE) were the ﬁrst choice in providing an enzyme platform
for engineering novel catalytic activity to degrade OPs. Limited success
was met with the BuChE mutant G117H [5] and the double mutant
G117H/E197Q to hydrolyze sarin, and later soman [6]. While the con-
struction of these engineered bioscavengerswith novel catalytic activity
was encouraging, the pseudo ﬁrst order rate constant of BuChE G117H
for somanwas found to be too slow to provide sufﬁcient in vivo protec-
tion against this OP [5,7]. We sought other enzymes within the plasma
that could serve as an enzyme platform for mutagenesis. Herein we
describe engineering pPAF-AH with a general base catalyst in positions
close to the active site serine, similar to those constructed in BuChE, in
an attempt to improve dephosphorylation rates.
Plasma PAF-AH inactivates the potent phospholipid mediator
platelet-activating factor (PAF) and other structurally similar bioactive
lipids produced in response to oxidative damage [8]. PAF is an acetylat-
ed derivative of glycerophosphocholine with an ether linked 16-carbon
chain attached to carbon 1, and it is poorly soluble in the aqueous phase.
Produced by platelets, basophils, eosinophils, neutrophils, and endothe-
lial cells, it modulates platelet aggregation, bronchoconstriction, inﬂam-
mation, shock, and vascular ischemia leading to stroke [9]. Bound to
both low-density lipoproteins (LDL) and high-density lipoproteins
(HDL), pPAF-AH inactivates PAF by catalyzing a phospholipase A2
esterolysis at the sn-2 position, producing lyso-PAF and acetate. Based
on this activity and its association with lipoprotein in circulation,
pPAF-AH is described as a lipoprotein-associated phospholipase A2.
We have previously expressed and puriﬁed active human pPAF-AH in
bacteria and solved the crystal structure with tabun (PDB 3F98), sarin
(PDB 3F96) and soman (PDB 3F97) adducts [10]. Informedby these struc-
tures, we made a limited series of single point amino acid substitutions
designed to explore novel dephosphorylation of the active site serine.
We characterized the interactions of the pPAF-AH mutants with ester
and OP substrates to determine their activity. Encouraging results from
one mutation (W298H) show promise that a protein engineering
approach with pPAF-AH can have utility in the development of biologicalscavengers capable of providing protection, in vivo, from these highly
toxic OPs.2. Material and methods
2.1. Molecular modeling
Structures of human pPAF-AH [10] were used to identify residues of
interest surrounding active site residues S273 andH351.While histidine
mutations at positions W298, F322, and L153 are the focus of this
project, other point mutations were constructed to explore how active
site substitutions could inﬂuence substrate binding and catalysis. The
following mutations were constructed: W298H, W298F, W298Y,
W298D, W298A, F322H, F322R, F322K, and L153H. Modeling was con-
ducted using the programVMD (VisualMolecular Dynamics, University
of Illinois, Urbana-Champaign). We used the Site Finder application
from the programM.O.E. (Molecular Operating Environment; Chemical
Computing Group Inc., Montreal, Canada) to map the active site
residues and void volume by packing 1 Å3 spheres and applying solva-
tion and void rules dictated by M.O.E. applications. Amino acid align-
ment for pPAF-AH and other proteins was performed using the
program ClustalW (Conway Institute, University College, Dublin,
Ireland).2.2. Bacterial expression
Synthetic vector sequences of nine mutant pPAF-AHs and a WT
pPAF-AH sequence were synthesized de novo (GeneArt AG,
Germany) in the pGEX-4T3 vector (GE Healthcare, Mickleton, NJ)
containing a glutathione-S-transferase fusion partner at the amino
terminus and a linker region containing a thrombin cleavage site.
Ten micrograms of the lyophilized plasmids was resuspended in
tris-ethylenediaminetetraacetic acid (EDTA) buffer. One liter of
Luria–Bertani Broth media plus ampicillin (50 μg/ml) was inoculated
with BL21 DE3 cells (Invitrogen Life Technologies, Carlsbad, CA), after
heat-shock transformation with 20 ng of expression vector containing
the pPAF-AH synthetic vector. The cultures were grown at 37 °C until
they reached 0.6 OD units at A600. Cells were induced to express using
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; Invitrogen Life
Technologies, Carlsbad, CA) and harvested after 4 h of induction at 37
°C. Mock transformation and expression with empty pUC19 vector
were processed in the same fashion as WT pPAF-AH.
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Bacterial cells were lysed by sonication on ice in lysis buffer (50mM
Tris, 150mMNaCl, 1mMEDTA, 0.5mMdithiothreitol (DTT), 0.2% Triton
DF-116, 1 mM phenylmethylsulfonyl ﬂuoride at pH 8.0). Cellular debris
was separated by centrifugation. Supernatant from the disrupted cell
mixture was added to glutathione sepharose 4B resin (GE Healthcare,
Mickleton, NJ) for 30 min at 4 °C with gentle inversion. The resin was
washed 5 times with 4 bed volumes (40 ml) of wash buffer (50 mM
Tris, 150 mM NaCl, 1 mM EDTA, 0.5 mM DTT, 0.2% Triton DF-116 at
pH 8.0). The elution buffer was made from the wash buffer by the
addition of 20 mM reduced glutathione. The column was eluted with
2 bed volumes (20 ml), and the elute was concentrated 30-fold using
10 K molecular weight cut-off spin columns (EMD Millipore, Billerica,
MA). Elution buffer was dialyzed against 10 mM Tris buffer pH 8.0.
Protein concentrations were estimated using BCA™ protein assay kit
(Thermo Fischer Scientiﬁc, Waltham, MA).
2.4. Substrate and gas chromatography/mass spectroscopy assay
Assays for pPAF-AH activity were performed with either para-
nitrophenyl butyrate (PNPB; Sigma-Aldrich, St. Louis, MO) or 2-thio PAF
(Cayman Chemical Co., Ann Arbor, MI). PNPB was dissolved in ethanol
and diluted to 5–1000 μM using 10 mM Tris buffer pH 8.0. Assays for
PNPB hydrolysis were conducted bymeasuring the change in absorbance
at 410 nm (extinction coefﬁcient Ɛ410 = 16,300 M−1 cm−1 for nitrophe-
nol) on a Spectramax Plus 384microplate reader (Molecular Devices Inc.,
Sunnyvale, CA). The KM and Vmax values were determined by ﬁtting the
data to the Michaelis-Menten equation (v0 = Vmax[S]/(KM+ [S])). Turn-
over number (kcat) was determined by dividing Vmax by total enzyme
concentration. BuChE used in these assays was puriﬁed from outdated
human plasma (Baxter BioScience).
The substrate 2-thio PAF was diluted to a stock concentration of
105 μM using 10 mM tris adjusted to various pH values. Assays were
conducted as follows: 10 μL of 105 μM 2-thio PAF, and 5 μL of 20 mM
5,5′-dithiobis-2-nitrobenzoic acid (DTNB) were added to 190 μL of
10 mM Tris in a modiﬁed Ellman assay [11]; 5 μL of protein sample
was added to the mixture and read in a microplate reader at 412 nm
for 1 h using the slope from the linear portion of the curve to determine
the rate. An extinction coefﬁcient of 13,600 M−1 cm−1 for the reaction
product was used to convert A412 nm to concentration of consumed
DTNB. Experiments were conducted at a single substrate concentration
(5 μM), which was slightly above the critical micelle concentration for
C-16 PAF at 1.1 μM [12].
The stereoselectivity of hydrolysis of soman by WT and mutant
pPAF-AHs was studied using gas chromatography/mass spectrometry
(GC/MS) methods modiﬁed from Yeung et al. [13]. All mutants were
screened for OP hydrolase activity. Puriﬁed pPAF-AH was incubated at
room temperaturewith aﬁxed concentration (1mM) for screening spe-
ciﬁc activity or various concentrations of racemic soman (10.4 mM
stock) to develop kinetic parameters. At various time points (t = 0,
15, 30, 45, and 60 min), 100 μl of the mixture was extracted with an
equal volume of dry ethyl acetate containing 50 μM diisopropyl
ﬂuorophosphates (DFP) as an internal standard. The majority of the or-
ganic layer containing the unreacted soman was removed and passed
over type 4A (grade 514) alumina-silicate molecular sieve to remove
water. Samples were transferred to 11 mm crimp top vials for GC/MS
analysis. One-microliter samples were autoinjected and components
separated using an Agilent 6890 gas chromatograph ﬁtted with a
20 m × 0.25 mm inside diameter Chiraldex gamma-cyclodextrin
triﬂuoroacetyl column with 0.125 μm ﬁlm thickness (Sigma-Aldrich).
The gas chromatograph was interfaced to an Agilent 5973 mass
spectrometer with an electronic impact ion source operated under
selected ion monitoring mode. Three ions (m/z 69, 101 and 127) were
monitored for DFP, and two ions (m/z 69 and 99) were monitored for
soman. Quantiﬁcation was accomplished using m/z = 127 for DFP andm/z 99 for soman. For each sample, the total area under the curve for
each isomer was used to determine the relative stereoselectivity.
Peaks were normalized against the internal standard DFP peak to
account for pipetting and instrument sampling errors during sample
analysis.
3. Results
We have previously crystallized and reﬁned OP adduct models of
pPAF-AH (Fig. 2A) following inactivation with tabun, sarin and soman
[10]. Fig. 2A depicts a ribbon structure of pPAF-AH adducted to soman
[10]. From these structures we determined residues F322, W298, and
L153 (Fig. 2B) to be in close proximity to the active site serine (S273),
which sits at the apex of a trough that provides potential binding sites
for long, bulky substrates. These three residues of interest surround
S273 and are essentially at the nine, twelve, and three o'clock positions,
respectively, with the majority of the active site trough occupying the
six o'clock position if S273 is consider the center point.W298 sits in a po-
sition at twelve o'clock and forms a “backboard” for the apex of the active
site trough behind S273. In addition to these three sites, we mapped res-
idues that deﬁne the active site pocket. Using the Site Finder application in
M.O.E., residues identiﬁed as lining the active site of pPAF-AHand the per-
centage of each characteristic are listed in Table 1. The volume of the ac-
tive site void was calculated to be 828 Å3. For comparison purposes, we
also calculated the active site void for human BuChE (PDB 1P0I) to be
582 Å3 using the same modeling software and parameters.
The effects mutations have on activity in pPAF-AH were examined
against the ester substrates PNPB and 2-thio PAF. We were able to
determine kcat and KM values from PNPB hydrolysis (Table 2). PNPB
esterolysis activity for mutants W298Y, W298D, W298A and L153H
was not sufﬁcient to develop kinetic parameters, because of either low
activity or high variability among the data points. Mutations at the
F322 position, which were all polar basic substitutions, displayed (on
average) a 70% decrease in catalytic efﬁciency (kcat/KM). Only the
mutations W298H and W298F displayed kcat/KM values that were 60%
and 55% of WT, respectively. Surprisingly, KM values were reduced for
bothmutants but were not signiﬁcantly different fromWT. A pH proﬁle
in 10 mM Tris buffer was conducted with 2-thio PAF against all the
pPAF-AH mutants and WT to determine optimal activity (Fig. 3). With
the exception of W298H, all mutants showed less speciﬁc activity than
WT at all pH values tested (pH 3.10, 4.90, 6.50, 6.90, 7.95 & 8.95).
Wild-type pPAF-AH reached maximal activity at pH 7.95 The pH rate
proﬁle forW298HmirroredWT except that activity was elevated across
all pH values measured, andW298H reachedmaximal activity at slight-
ly more acidic conditions (pH 6.9). AlthoughW298H showed enhanced
activity against 2-thio PAF (Fig. 3), it had reduced catalytic efﬁciency
against PNPB (Table 2). L153H was the only mutant tested that was
inactive against both PNPB and 2-thio PAF.
Our long-term goal of developing pPAF-AH as a catalytic
bioscavenger for OP nerve agents required analysis of the interactions
and reactivity between the enzyme and an OP. The reactivity of AChE
and BuChE with OP nerve agents is extremely fast, and a bimolecular
rate constant for inactivation can be difﬁcult to capture. It was surpris-
ing to ﬁnd that wild-type pPAF-AH had an unusually slow reactivity
with racemic soman (Fig. 4). At room temperature, various molar ratios
of enzyme to nerve agent (1:10, 1:100, and 1:1000) for pPAF-AH and
BuChE were examined. In the continuous presence of nerve agent,
pPAF-AH required nearly 100 times more nerve agent to develop an
inhibition curve that resembled that of BuChE (comparing
BuChE:soman 1:10 & pPAF-AH:soman 1:1000). Even with this differ-
ence in molar ratios, pPAF-AH required nearly triple the time to reach
zero activity. These results were unexpected and would not be an
optimal choice for developing a catalytic bioscavenger.
Racemic soman hydrolysis was initially measured using a modiﬁed
GC/MS assay and a ﬁxed concentration of soman. Racemic soman is a
mixture of four separate isomers (PSCS/PSCR/PRCS/PRCR), and the
Fig. 2. The structure of pPAF-AH complexedwith soman (9). Panel A shows a space-ﬁlled,
partially cut-down structure of pPAF-AH with soman adducted to S273 and shows the
residues surrounding the active site S273 and H351. F322, W298 and L153 are sites for
mutagenesis. Panel B shows the approximate angle (yellow arc) and distance (red line)
to the S273 Oγ for F322 if we assume S273 is the vertex and the direction to the active
site histidine (H351) forms one side (red line). F322 is closest to S273 Oγ at 4.8 Å and
sits close to H351 at approximately 44°. Panel C shows L153 is offset from H351 by
approximately 121°, but it is more than 5.8 Å away from S273 Oγ. Panel D shows W298
offset from H351 by approximately 126°, and at a position of 6.7 Å from S273 Oγ.
Table 1
Amino acid residues deﬁning the active site pocket of plasma PAF-AH.
Hydrophobic Polar (uncharged) Polar (charged)
W97, L107, F110, L111, M117,
L121, L124, F125, L153, A155,
F156, L159, F274, W298, F322,
V350, F354, A355, F357, A360,
I365, L369, L371
S108, G152, G154, Y160, S185,
S273, G275, S319, Y321, Q352,
N353, T358, T361
H151, H272,
H351, D356,
K370
56% 32% 12%
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umn (Fig. 5). Histidine mutants F322H and L153H showed no enhanced
hydrolysis of racemic soman above those rates observed for wild-type
pPAF-AH. These twomutants andwild-type pPAF-AH have relative activ-
ities less than 4 nmol/h/μg protein each for racemic soman. In contrast,
W298H has relative activity for racemic soman hydrolysis closer to 26
nmol/h/μg. There was no signiﬁcant difference between F322H, L153H,
and wild-type values. Each stereoisomer was hydrolyzed by W298H
with roughly equivalent rates (within error) demonstrating that
W298H displays no stereoselective preference for hydrolysis of soman.
Subsequent experiments examined saturation curves for the
W298H soman hydrolytic activity at pH 7.5 and 8.0 (Fig. 6). Steady
state kinetic parameters of W298H at pH 8 (n = 5) were observed to
be nearly linear with no saturation of the curve. A maximal kcat of
29 min−1 was developed with a calculated KM of 6.8 mM. However,
this was an extrapolation beyond the limits of our assay, since soman
concentrations greater than 2 mM could not be used in experiments
due to safety related constraints. At pH 7.5 (n = 3), a kcat of 5 min−1
was determined with a KM of 593 μM. This represents a catalytic efﬁ-
ciency of 8.4 × 103 M−1 min−1.4. Discussion
Serinehydrolases have thepotential to be converted intoOPhydrolyz-
ing platforms because of the inherent nature of the OP inhibitors to act as
hemi-substrates and to be locked into the ﬁrst half of the esterolysis
mechanism. After stereo-inversion around the adducted phospho-
center, the face of the developing intermediate is protected from reactive
nucleophiles (e.g., activated water molecule) coordinated by the native
amino acid residueswithin the active site during the secondhalf of the re-
action, and any ensuing hydrolysis of the intermediate is blocked, leaving
the enzyme in an inactivated state (Fig. 1B). Two competing reactionswill
ensue: hydrolysis of the phospho-serine adduct, which is extremely slow
for most esterases, or a mono dealkylation of the phospho-serine adduct
which generates an “aged” enzyme. “Aging” rates are dependent on the
type of OP used for inhibition, and “aged” enzymes are completely refrac-
tory to spontaneous or oxime-assisted reactivation. Recently twoTable 2
Kinetic parameters for p-nitrophenylbutyrate hydrolysis by pPAF-AH enzymes.a
kcat (min−1)b KM (μM) kcat/KM (min−1 μM−1)b
WT 3.5 ± 0.60 1.1 ± 0.35 3.13 ± 1.12
W298H 0.62 ± 0.07 0.66 ± 0.21 0.94 ± 0.31
W298F 0.86 ± 0.19 0.73 ± 0.42 1.18 ± 0.73
W298Y n.d. n.d. n.d.
W298D n.d. n.d. n.d.
W298A n.d. n.d. n.d.
F322H 0.38 ± 0.08 0.53 ± 0.29 0.71 ± 0.42
F322R 0.35 ± 0.07 0.64 ± 0.35 0.54 ± 0.32
F322K 0.41 ± 0.07 0.53 ± 0.24 0.77 ± 0.36
L153H n.d. n.d. n.d.
a The activity is reported for kcat (min−1) and KM (μM) at pH 8.0 for the substrate PNPB.
Each value represents an average of three independent experiments±standard deviation.
n.d. = not detected.
b A one-way ANOVA followed byDunnett's test determined a signiﬁcant difference (P b
0.01) between wild-type and all other mutants for kcat and kcat/KM, but there was no sig-
niﬁcant difference in KM.
Fig. 3. Speciﬁc activity of wild-type and single point mutants of recombinant pPAF-AH at
various pH levels against 2-thio PAF in 10mM Tris buffer. Each data point is an average of
three independent experiments (error bars show standard deviation).
Fig. 5. Speciﬁc activity screen of histidine mutants and WT pPAF-AH for each of the four
stereoisomers of soman (GD). Each bar represents the average of three independent ex-
periments. Mock expressions were run in parallel, and their average value was subtracted
from each of the experimental bars. A one-way ANOVA followed by Bonferroni's multiple
comparison test determined a signiﬁcant difference (P b 0.001) between W298H and all
other mutants.
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non-aged crystal structures of humanCaE complexed to soman and tabun
[14], and PAF-AH1b (a groupVIII-PLA2) complexedwith sarin and soman
[15] have been reportedmaking themmore attractive platforms to devel-
op as catalytic bioscavengers for OP nerve agents.
Conditions may vary across the serine hydrolase family of enzymes,
but two factors need to be satisﬁed for hydrolysis of the phosphorylated
serine to be executed: access to water molecules and an opportunely
positioned general base to activate the water molecule for addition
onto the appropriate face of the phospho-enzyme intermediate. It can
be postulated that pPAF-AH H351 is the primary base (together with
its dyad partner D296) in the active site and is suited for hydrolysis of
an esteriﬁed active site serine, but sits in an unfavorable position for
hydrolysis of a phosphorylated serine. Substitution of a residue close
to the active site serine to a different amino acid that is able to functionFig. 4. A comparison of soman (GD) inhibition rates between BuChE and recombinant
wild-type pPAF-AH as a function of uninhibited activity. Molar ratios of enzyme to GD
are as follows: BuChE:GD 1:10 (purple diamond); pPAF-AH:GD 1:1000 (green circle);
pPAF-AH:GD 1:100 (red square); pPAF-AH:GD 1:10 (blue triangle).as a general base catalyst is the model that we employed here and is
the one that historically has held the most promise for engineering
novel OP hydrolase activity [6]. It can be postulated that access to the
phospho-serine adduct by the attacking water molecule for the
W298H mutant is less restricted or positioned more accurately (~126°
away from H351 and ~7 Å from S273; Fig. 2D) than for the other
mutants tested due to the novel turnover observed in this mutant.Fig. 6. Saturation kinetic curves for soman (GD)hydrolysis byW298H in 10mMTris buffer
at pH 7.5 and pH 8.0. Rates of hydrolysis were followed across 6 substrate concentrations
by GC/MS. Each point represents an average of 3 (pH 7.5) or 5 (pH 8.0) replicates ± stan-
dard deviation. Mock expression experiments were run in parallel, and subtracted from
each point to account for spontaneous and non-speciﬁc hydrolysis.
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[5] converting BuChE into a platform that could hydrolyze sarin, VX and
other OP compounds by substituting a histidine for a glycine (G117H)
at a key active site position,which partially forms the putative oxyanion
hole. However, theG117Hmutant of BuChE could not hydrolyze soman.
Following another round of rational protein engineering, synergy
ensued and soman hydrolysis was achieved with the addition of
the E197Q mutation to the G117H platform [6]. Broomﬁeld reported
a rate constant for dephosphorylation after soman inhibition for
G117H/E197Q to be 0.06 min−1. Here we achieved soman hydrolysis
that is two orders of magnitude faster with the single point mutation
of W298H and a kcat of 5 min−1. This is a remarkable achievement for
any engineered enzyme platform but especially so for pPAF-AH, given
that wild-type inactivation using soman is exceptionally slow (Fig. 4).
This is the ﬁrst instance since BuChE G117H that OP-hydrolase activity
with reportable rates has been created on any enzyme platform from
a single amino acid substitution.
By developing rational, active site mutations in pPAF-AH, we have
not only engineered a signiﬁcant OP hydrolase bioscavenger, but also
learned more about the catalytic mechanism and functional properties
of pPAF-AH. While a full description of the catalytic mechanism and
substrate binding sites will certainly require further mutations and
experiments, these studies elucidate some facets of the mechanism. It
is not surprising that most of the mutants, including W298H and
W298F, lost signiﬁcant activity against the PNPB substrate (Table 2).
W298 appears to be vital for substrate interactions with S273, based
on geometric observations and the fact that substituting W298 with
alanine (W298A) dramatically reduced activity for both ester substrates
(Table 2 & Fig. 3). On this assumption, it is reasonable that conservative
substitutions like W298F retained a larger portion of activity compared
to other mutants. Values for KM across all the mutations were not
signiﬁcantly different from wild-type (Table 2). The W298H substitu-
tion is unusual in that a polar charged (positive at pH b 6.5) group did
not eliminate activity but instead only reduced it slightly for PNPB,
and enhanced it for 2-thio PAF (Fig. 3).
The ability of pPAF-AH to interact with substrates from both the
aqueous and the lipid interfacial surface makes it an interesting
candidate for development as a catalytic bioscavenger, as this enzyme
could target OP substrates that partition into lipid dense compartments
in vivo and environments ex vivo. TestingWT pPAF-AH in a more native
state, perhaps in the presence of puriﬁed liposomes or artiﬁcial lipid
rafts, may result in a better understanding of the interaction between
pPAF-AH and OP inhibitors like soman. There is evidence to suggest
that pPAF-AH may have its activity modulated by lipid composition
and may undergo interfacial activation upon binding to lipoproteins
[16].
During inactivation of serine hydrolases by soman, the product of in-
hibition is a chiral phosphorylated serine at the active site. The chirality
adopted is dependent uponwhich of the two phosphorus stereoisomers
of soman that reacted during phosphorylation. One possibility is that
the more toxic stereoisomers (PsCs/R) of soman [17] bindmore rapidly,
forming a product that is more difﬁcult to hydrolyze because of its
conﬁguration. Alternatively, adduct formation with the Ps isomers
may result in a conﬁguration that is more susceptible to a subsequent
dealkylation process (e.g., “aging”) that prevents enzyme reactivation.
In these experiments we separated each soman stereoisomer after
hydrolysis of the racemic compound to identify stereoselectivity, if
any. Therefore we must consider differences observed in activities
when comparing rates of hydrolysis for “racemic”OP compounds versus
hydrolysis of pure enantiomers in solutions for future experiments.
Preferential hydrolysis of the more toxic stereoisomers of OP nerve
agents is a major consideration in engineering and development of a
catalytic bioscavenger. As can be seen from the BuChE G117H/E197Q
data [6], there are differences in the rates of hydrolysis for each stereo-
isomer of soman. We observed no signiﬁcant difference in the rates of
hydrolysis for any of the soman stereoisomers when using W298HpPAF-AH as seen in Fig. 5. This is an advantage in further developing
our pPAF-AH enzyme platform, because hydrolysis of the more toxic
stereoisomers of an OP will likely not be restricted.
The non-selective OP hydrolysis seen in pPAF-AH W298H may be
because it has a permissive active site that allows for unrestricted bind-
ing to each of the stereoisomers of soman, as corroborated by the crystal
structure of soman-adducted pPAF-AH [10]. From previous crystal
structures of OP-pPAF-AH adducts with paraoxon [9] and soman [10]
it became evident that binding pockets within the active site can clearly
accommodate large isopropyl or pinacolyl groups with equivalent
occupancy and, thereby, do not preclude speciﬁc enantiomeric
preference for adduction to the active site serine. The catalytic triad of
pPAF-AH (S273, H351 and D296) sits at the edge of a large trough or
groove on the protein, which is possibly present to accommodate bind-
ing sites for long alkyl side chain of potentially different lengths as found
in the native substrate, platelet-activating factor. The trough may be
useful in assisting either substrate binding or hydrolysis product
expulsion from the active site. In the BuChE G117H/E197Q mutant, a
likely reason for the stereoselective hydrolysis seen may be the more
restrictive nature of the active site in BuChE, which is found at the bot-
tomof a deep gorge similar to that of AChE [18]. This active site architec-
ture only accepts a limited number of substrates, and thusmay preclude
some stereoisomers from having direct access to the active site serine.
We calculated the active site volume of wild-type BuChE to be 582 Å3,
which is similar to the volume of 496 Å3 reported by other researchers
[3]. Here we report the active site volume for pPAF-AH (including the
trough) to be 828 Å3, which is close to 1.5 times the size found in
BuChE, but signiﬁcantly smaller than 3014 Å3 reported for CaE [3]. The
difference in active site volumes and architectural constraints, and the
positioning of the catalytic triad within the active site are features that
contribute to the non-stereoselective hydrolysis of soman by pPAF-AH
W298H.
Variations in pH can have dramatic effects on activity. In the case of
W298H, we observed enhanced activity overWT pPAF-AH across all pH
levels tested, as seen in Fig. 3. The shift in pH optima fromWT at pH 8.0
to W298H at pH 6.9 is indicative of enhancement of an ionizable
mechanism as the solution becomes more acidic. Hydrogen bonds
help stabilize both intermediate and transition states within an enzyme
reaction mechanism, and provide approximately 5 kcal/mol for each
hydrogen bond. These stabilizing hydrogen-bonds are generally local-
ized on enzymes in deﬁned pockets. A particular pocket known as the
“oxyanion hole” present in pPAF-AH stabilizes the developing anion
formed at the intermediate substrate step, with the proton donors
coming directly from the amino acid residue or from the amides within
the peptide backbone. For pPAF-AH, an oxyanion hole is formed by
hydrogen bond interactions with the amide nitrogens of L153 and
F274 [10]. BuChE has an oxyanion hole with at least three hydrogen
bonding partners. Successful reactivation was achieved in BuChE
when a histidine was substituted within the oxyanion hole at position
117. Potential OP hydrolase activity in the L153H pPAF-AH was antici-
pated because this substitution is essentially analogous to BuChE
G117H. However, our L153H mutant showed no OP-hydrolase activity
greater than wild-type, and was inefﬁcient at hydrolyzing both ester
substrates.We believeW298Hmutant supports activation of an incom-
ing water molecule positioned in the proper face of the phospho-serine
intermediate, analogous to BuChE G117H, without the loss of an
oxyanion hole interaction, and promotes dephosphorylation to regener-
ate the enzyme and expel hydrolyzed nerve agent by-products.
5. Conclusions
In order to evaluate the signiﬁcance of ourW298Hmutant, wemust
consider the catalytic power needed to overcome lethal concentrations
of nerve agents. Recent work has demonstrated that an engineered
paraoxonase-1 (PON1) needs a kcat/KM of 5× 107M−1min−1 to provide
protection to guinea pigs against a lethal dose of cyclosarin with no
1815S.D. Kirby et al. / Biochimica et Biophysica Acta 1854 (2015) 1809–1815other therapeutics administered [19]. This is signiﬁcantly different from
the kcat/KM for our W298H at 8 × 103 M−1 min−1. However, from a
historical perspective, WT PON1 has limited catalytic power against G-
type OPs [20] and yet through directed evolution, researchers have
been able to optimize catalytic efﬁciency from b198 M−1 min−1 in
WT PON1 to N1.7 × 107 M−1 min−1 in an evolved mutant [21].
Paraoxonase-1 and pPAF-AHare targeted to the same site as both are lo-
calized on HDL and LDL lipoproteins in mammalian blood. We view
PAF-AH as a risk-mitigating alternative platform to PON1, in the event
that unanticipated problems with PON1 are discovered. PAF-AH, unlike
PON1, is a serine hydrolasewhich has been overlooked as a platform for
OP scavenger development until now. Our pPAF-AH soman-asemutant
(W298H) opens the door for future protein engineering projects
including a directed evolution approach that is currently underway.
Acknowledgments
Special thanks to Dr. Clarence Broomﬁeld for his guidance for so
many years, and to Dr. David Lenz for his support while at USAMRICD.
We thank Dr. Mark Zottola for guiding us through the Site Finder
program in M.O.E. and for the many insightful discussions. Special
thanks to Mr. Rick Smith and Dr. Shane Kasten for helping us on our
way through the GC/MS analysis.
References
[1] P. Taylor, Anticholinesterase Agents, 10th ed. McGraw-Hill, New York, 2001.
[2] T. Suzuki, H. Morita, K. Ono, K. Maekawa, R. Nagai, Y. Yazaki, Sarin poisoning in
Tokyo subway, Lancet 345 (1995) 980.
[3] D.M. Maxwell, K. Brecht, A. Saxena, S. Feaster, B.P. Doctor, Comparison of
cholinesterase and carboxylesterase as scavengers for organophosphorus
compounds, Structure and Function of Cholinesterases and Related Proteins,
Plenum Press, New York 1998, pp. 387–392.
[4] C.A. Broomﬁeld, S.D. Kirby, Progress on the road to new nerve agent treatments, J.
Appl. Toxicol. 21 (Suppl 1) (2001) S43–S46.
[5] O. Lockridge, R.M. Blong, P. Masson, M.T. Froment, C.B. Millard, C.A. Broomﬁeld, A
single amino acid substitution, Gly117His, confers phosphotriesterase (organophos-
phorus acid anhydride hydrolase) activity on human butyrylcholinesterase,
Biochemistry 36 (1997) 786–795.
[6] C.B. Millard, O. Lockridge, C.A. Broomﬁeld, Organophosphorus acid anhydride
hydrolase activity in human butyrylcholinesterase: synergy results in a GDase,
Biochemistry 37 (1998) 237–247.[7] B.C. Geyer, L. Kannan, P.E. Garnaud, C.A. Broomﬁeld, C.L. Cadieux, I. Cherni, S.M.
Hodgins, S.A. Kasten, K. Kelley, J. Kilbourne, Z.P. Oliver, T.C. Otto, I. Puffenberger,
T.E. Reeves, N. Robbins 2nd, R.R. Woods, H. Soreq, D.E. Lenz, D.M. Cerasoli, T.S.
Mor, Plant-derived human butyrylcholinesterase, but not an organophosphorous-
compound hydrolyzing variant thereof, protects rodents against nerve agents,
Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 20251–20256.
[8] S.M. Prescott, G.A. Zimmerman, D.M. Stafforini, T.M. McIntyre, Platelet-activating
factor and related lipid mediators, Annu. Rev. Biochem. 69 (2000) 419–445.
[9] G. Montrucchio, G. Alloatti, G. Camussi, Role of platelet-activating factor in
cardiovascular pathophysiology, Physiol. Rev. 80 (2000) 1669–1699.
[10] U. Samanta, S.D. Kirby, P. Srinivasan, D.M. Cerasoli, B.J. Bahnson, Crystal structures of
human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents
exhibit non-aged complexes, Biochem. Pharmacol. 78 (2009) 420–429.
[11] G.L. Ellman, Tissue sulfhydryl groups, Arch. Biochem. Biophys. 82 (1959) 70–77.
[12] W. Kramp, G. Pieroni, R. Pinckard, D. Hanahan, Observations on the critical micellar
concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its
homologs and analogs, Chem. Phys. Lipids 35 (1984) 49–62.
[13] D.T. Yeung, J.R. Smith, R.E. Sweeney, D.E. Lenz, D.M. Cerasoli, Direct detection of
stereospeciﬁc GD hydrolysis by wild-type human serum paraoxonase, FEBS J. 274
(2007) 1183–1191.
[14] C.D. Fleming, C.C. Edwards, S.D. Kirby, D.M. Maxwell, P.M. Potter, D.M. Cerasoli, M.R.
Redinbo, Crystal structure of human carboxylesterase 1 in covalent complexes with
the chemical warfare agents soman and tabun, Biochemistry 46 (2007) 5063–5071.
[15] T.M. Epstein, U. Samanta, S.D. Kirby, D.M. Cerasoli, B.J. Bahnson, Crystal structures of
brain group-VIII phospholipase A2 in nonaged complexes with the organophospho-
rus nerve agents soman and sarin, Biochemistry 48 (2009) 3425–3435.
[16] A.H. Pande, V.A. Tillu, Membrane lipid composition differentially modulates the
function of human plasma platelet activating factor-acetylhydrolase, Biochim.
Biophys. Acta 1811 (2011) 46–56.
[17] H.P. Benschop, C.A. Konings, J. Van Genderen, L.P. De Jong, Isolation, anticholinester-
ase properties, and acute toxicity in mice of the four stereoisomers of the nerve
agent GD, Toxicol. Appl. Pharmacol. 72 (1984) 61–74.
[18] Y. Nicolet, O. Lockridge, P. Masson, J.C. Fontecilla-Camps, F. Nachon, Crystal structure
of human butyrylcholinesterase and of its complexes with substrate and products, J.
Biol. Chem. 278 (2003) 41141–41147.
[19] F. Worek, T. Seeger, M. Goldsmith, Y. Ashani, H. Leader, J. Sussman, D. Tawﬁk, H.
Thiermann, T. Wille, Efﬁcacy of the rePON1 mutant IIG1 to prevent cyclosarin
toxicity in vivo and to detoxify structurally different nerve agents in vitro, Arch.
Toxicol. 88 (2014) 1257–1266.
[20] S. Kirby, J. Norris, J. Smith, B. Bahnson, D. Cerasoli, Human paraoxonase double mu-
tants hydrolyze V and G class organophosphorus nerve agents, Chem. Biol. Interact.
203 (2012) 181–185.
[21] R. Gupta, M. Goldsmith, Y. Ashani, Y. Simo, G. Mullokandov, H. Bar, M. Ben-David, H.
Leader, R. Margalit, I. Silman, J. Sussman, D. Tawﬁk, Directed evolution of hydrolases
for prevention of G-type nerve agent intoxication, Nat. Chem. Biol. 7 (2011)
120–125.
